Myomo Inc (MYO)
:MYO
Top Page
Myomo
(MYO)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.65
▼(-3.97% Downside)
Action:ReiteratedDate:04/09/26
The score is pressured primarily by weak financial performance (ongoing losses, higher cash burn, and reduced equity cushion) and bearish technicals (price below key moving averages with negative MACD). Valuation provides limited offset because the negative P/E reflects unprofitable operations and there is no dividend yield support.
Positive Factors
High Gross Margins
Sustained mid-60% gross margins point to favorable unit economics and pricing power in Myomo's device business. Durable product-level profitability provides a cushion against sales volatility, enabling reinvestment in clinical support, R&D, and channel development if revenue stabilizes.
Negative Factors
Persistent Negative Cash Flow
Consistent negative operating and free cash flow, with significant 2025 cash burn, increases financing dependency and execution risk. Ongoing outflows limit capacity to scale sales, invest in clinical rollouts, or withstand reimbursement delays without dilutive capital or costly debt.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained mid-60% gross margins point to favorable unit economics and pricing power in Myomo's device business. Durable product-level profitability provides a cushion against sales volatility, enabling reinvestment in clinical support, R&D, and channel development if revenue stabilizes.
Read all positive factors
Myomo (MYO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.19M
Dividend YieldN/A
Average Volume (3M)385.50K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth64.99%
EPS Growth-25.54%
CountryUS
Employees184
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding38,511,715
10 Day Avg. Volume267,868
30 Day Avg. Volume385,495
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue0.79
Enterprise Value/Gross Profit1.20
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$4.32Price Target Upside535.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$46.97M
Myomo Business Overview & Revenue Model
Company Description
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis ...
How the Company Makes Money
Myomo makes money primarily by selling and providing its wearable myoelectric orthosis devices (notably the MyoPro) to patients, typically through the clinical prescription and fitting process. Revenue is generated from the delivered device and as...
Myomo Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with notable revenue growth and strategic expansions, particularly in international markets and the O&P channel. However, challenges such as decreased gross margin, increased operating loss, and high cash burn were significant concerns. The company's reaffirmation of financial guidance and steps to optimize costs and advertising were positive, but the issues with Medicare Advantage revenue and increased losses present challenges.Positive Updates
Revenue Growth and International Success
Myomo reported a revenue of $10.1 million for Q3 2025, marking a 10% increase compared to the prior year, driven by record revenues in international markets, especially Germany.
Negative Updates
Decline in Medicare Advantage Revenue
Medicare Advantage revenue was down 18% compared to the prior year, constrained by high pre-authorization denial rates, resulting in a time-consuming appeals process.
Read all updates
Q3-2025 Updates
Positive
Negative
Revenue Growth and International Success
Myomo reported a revenue of $10.1 million for Q3 2025, marking a 10% increase compared to the prior year, driven by record revenues in international markets, especially Germany.
Read all positive updates
Company Guidance
During the Myomo Third Quarter 2025 Financial Results Conference Call, CEO Paul Gudonis provided guidance that the company anticipates achieving full-year 2025 revenue within the range of $40 million to $42 million, reflecting an over 23% increase compared to the previous year. This optimistic outlook is supported by a robust performance in the third quarter, where the company reported revenues of $10.1 million, driven by a 16% increase in MyoPro revenue units and strong international sales, notably a 63% rise in Germany. Additionally, the company is expanding its MyoConnect program and O&P channel to lower customer acquisition costs while also seeing a positive trend in Medicare Advantage authorizations. Myomo's strategic initiatives include expanding insurance coverage, reducing operating costs, and enhancing patient identification processes. CFO Dave Henry highlighted a gross margin of 63.8% and operating expenses totaling $10 million, with a focus on improving operating leverage and lowering cash burn in 2026. The company reiterated its commitment to scaling its business towards sustainable profitability and positive cash flow.Myomo Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
41
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.93M | 32.55M | 19.24M | 15.56M | 13.86M |
| Gross Profit | 26.89M | 23.19M | 13.18M | 10.25M | 10.31M |
| EBITDA | -12.64M | -5.04M | -7.71M | -10.13M | -9.93M |
| Net Income | -15.57M | -6.18M | -8.15M | -10.72M | -10.37M |
Balance Sheet | |||||
| Total Assets | 38.64M | 42.24M | 14.58M | 10.16M | 20.10M |
| Cash, Cash Equivalents and Short-Term Investments | 18.39M | 24.87M | 8.87M | 5.35M | 15.52M |
| Total Debt | 19.38M | 8.11M | 601.30K | 553.91K | 735.00K |
| Total Liabilities | 27.23M | 17.53M | 5.59M | 3.80M | 4.69M |
| Stockholders Equity | 11.40M | 24.71M | 8.99M | 6.36M | 15.41M |
Cash Flow | |||||
| Free Cash Flow | -16.25M | -4.65M | -6.32M | -10.35M | -9.87M |
| Operating Cash Flow | -14.51M | -3.29M | -6.17M | -10.23M | -9.55M |
| Investing Cash Flow | -7.06M | 259.98K | -2.03M | -310.79K | -326.46K |
| Financing Cash Flow | 11.43M | 20.93M | 9.71M | 376.86K | 13.17M |
Myomo Technical Analysis
Negative
0.68
Price Trends
0.76
Negative
0.85
Negative
1.11
Negative
Market Momentum
-0.02
Negative
43.76
Neutral
65.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYO, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.76, and below the 200-day MA of 1.11, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.76 is Neutral, neither overbought nor oversold. The STOCH value of 65.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYO.
Myomo Risk Analysis
Myomo disclosed 15 risk factors in its most recent earnings report. Myomo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Risks Related to Internal Controls Q4, 2025
2.
Cautionary statement regarding forward-looking statements Q4, 2025
3.
Risks Related to Our Operating and Financial Results Q4, 2025
Myomo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $31.32M | -1.58 | -312.04% | ― | -70.54% | 70.03% | |
50 Neutral | $50.20M | -2.73 | -2072.11% | ― | 27.90% | 1.62% | |
42 Neutral | $26.19M | -2.45 | -95.35% | ― | 64.99% | -25.54% | |
41 Neutral | $18.56M | -2.02 | -279.06% | ― | ― | ― | |
39 Underperform | $5.56M | -0.35 | -247.60% | ― | ― | 15.03% |
* Healthcare Sector Average
MYO
Myomo
0.68
-3.61
-84.15%
ECOR
Electrocore
6.21
0.69
12.50%
MODD
Modular Medical
5.10
-20.40
-80.00%
RBOT
Vicarious Surgical
0.78
-4.65
-85.64%
ADGM
Adagio Medical Holdings
1.41
0.63
80.77%
IINN
Inspira Technologies Oxy BHN
0.43
-0.20
-31.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.